DWA
CRBP icon

Dorsey Wright & Associates’s Corbus Pharmaceuticals CRBP Stock Holding History

Dorsey Wright & Associates’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-2,555
Closed -$20K – 289
2023
Q2 		$20K Buy
+2,555
New +$23K 0.01% 263
2020
Q3 		– Sell
-45
Closed -$11K – 315
2020
Q2 		$11K Buy
+45
New +$9.09K ﹤0.01% 219

Other funds holding CRBP

IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Dorsey Wright & Associates's CRBP Position: Q3 2023 in Review

Dorsey Wright & Associates sold out of Corbus Pharmaceuticals (CRBP) in Q3 2023, closing a stake of 2,555 shares — an estimated $20K sold.

Dorsey Wright & Associates first reported a position in CRBP in Q2 2020 and held it in 2 quarters. The position peaked at $20K in Q2 2023. 27 funds tracked by Wall St. Rank hold CRBP as of Q3 2023.

  • Dorsey Wright & Associates reported no remaining Corbus Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Dorsey Wright & Associates sold 2,555 Corbus Pharmaceuticals shares in Q3 2023, an estimated $20K.
  • Dorsey Wright & Associates first reported a position in Corbus Pharmaceuticals in Q2 2020 and held it in 2 quarters.
  • Dorsey Wright & Associates's Corbus Pharmaceuticals position peaked at $20K in Q2 2023.
  • 27 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q3 2023.

Based on Dorsey Wright & Associates's 13F filing for Q3 2023, filed 7 Nov 2023.